NEWNow you can listen to Fox News articles!
AstraZeneca announced this on Monday. two of its existing therapies have been recommended for the treatment of patients with certain high-risk breast cancers in the European Union, contributing to the development of the company’s oncology portfolio.
Lynparza, a cancer drug co-developed with US company Merck, has been approved for use on its own or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer.
Drug, which received a similar recommendation in the US in March, is a key AstraZeneca asset. It was recommended for patients with low or normal levels of a protein known as HER2, which is the target of several new treatments.
Enhertu, co-developed with the Japanese company Daiichi Sankyo, was another drug approved by the European Medicines Agency for the treatment of an aggressive form of fever. mammary cancer characterized by high levels of HER2.
Enhertu is seen as a major growth driver for AstraZeneca, with some analysts expecting a $10 billion sales peak. The drug is also expected to be approved this month for patients with low HER2 levels following recent successful trials.